DL-ICE Chemotherapy and Allogeneic Transplantation for Relapsed/Refractory PTCL
Author Information
Author(s): Kim Tong-Yoon, Kim Tae-Jung, Han Eun Ji, Min Gi June, Cho Seok-Goo, Jeon Youngwoo
Primary Institution: Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
Hypothesis
The combination of DL-ICE chemotherapy followed by allogeneic hematopoietic stem cell transplantation will improve outcomes for patients with relapsed/refractory peripheral T-cell lymphomas compared to conventional salvage therapy.
Conclusion
DL-ICE chemotherapy followed by allogeneic transplantation can lead to long-term survival in some patients with relapsed/refractory PTCL, even if they do not achieve complete remission.
Supporting Evidence
- The overall response rate to DL-ICE was 37.5%, with 30% achieving complete remission.
- The 5-year overall survival rate was significantly higher in the allo-HSCT group compared to chemotherapy alone (64.7% vs 18.3%).
- Advanced stage, EBV viremia, and non-CR status were identified as poor prognostic factors.
Takeaway
This study shows that a special treatment can help some people with a tough type of cancer live longer, even if they don't get completely better first.
Methodology
The study retrospectively analyzed 80 adult patients with relapsed/refractory PTCLs treated with DL-ICE chemotherapy followed by allogeneic hematopoietic stem cell transplantation.
Potential Biases
The study did not include a control group, which may introduce bias in interpreting the results.
Limitations
The study is retrospective and has a relatively small sample size, which may limit the generalizability of the findings.
Participant Demographics
The median age of participants was 48.5 years, with 56% male and various subtypes of PTCL represented.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI: 7.9–22.6 months for OS
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website